Keymed Biosciences, Inc. (HK:2162) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Keymed Biosciences Inc. has entered an exclusive license agreement with Platina Medicines Ltd, granting them rights to develop, manufacture, and commercialize the bispecific antibody CM336 outside China, Hong Kong, Macau, and Taiwan. The deal includes an upfront payment of $16 million to Keymed and potential milestone payments up to $610 million, along with royalties on sales. This agreement aims to expand Keymed’s global presence and maximize the commercial potential of its technology.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.